| Next 10 |
Ad
EVAX News and Press Evaxion Biotech A/S
News | Evaxion Biotech A/S (NASDAQ:EVAX)
-
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platform The collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub Afrigen responsible for the development and co...
-
AI-powered target discovery for a bacterial pathogen with a high medical need where no vaccine is currently available Evaxion’s proprietary AI-platforms EDEN™ and RAVEN™ will be utilized for rapid design of a completely novel vaccine candidate capable of eliciting bo...
-
Evaxion is the first organization to validate an AI model that outcompetes state-of-the-art vaccine development Evaxion's AI model predicts vaccine efficacy in infectious disease models These results mean using EDEN TM will allow for a faster, cheaper, and lower-risk vaccine developme...
-
2023-08-29 09:32:01 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion Biotech ADS GAAP EPS of -$0.21 misses by $0.01 Evaxion stock slumps ~10% despite developing AI tool for cancer therapy Evaxio...
-
COPENHAGEN, Denmark, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced: Evaxion has hired a new Ch...
-
2023-08-22 17:34:06 ET Evaxion Biotech A/S (EVAX) Q2 2023 Earnings Conference Call August 22, 2023, 10:00 AM ET Company Participants Per Norlen - Chief Executive Officer Jesper Nyegaard Nissen - Chief Operating Officer and Interim Chief Financial Officer Confer...
-
2023-08-18 13:35:12 ET More on Evaxion Biotech ADS Evaxion Biotech: Personalized Cancer Vaccine Biotech With Q4 2023 Catalyst Evaxion stock slumps ~10% despite developing AI tool for cancer therapy Evaxion stock surges ~25% on preclinical data for mRNA vaccine for ca...
-
Promising clinical data from Phase 1 and 2a studies with EVX-01 and EVX-02 were presented at AACR and ASCO in Q2 2023 A novel proprietary genetic vaccine adjuvant was presented at Evaxion’s R&D Day in May. The technology is an integral part of the next-generation cancer vaccine, EV...
-
2023-08-02 15:58:47 ET Summary Interim results from the phase 2 study, using EVX-01 for the treatment of patients with metastatic melanoma, is expected in Q4 of 2023. Positive preliminary results have already been established in using EVX-01 for metastatic melanoma patients and EV...
-
2023-08-01 18:00:01 ET Evaxion Biotech ( EVAX ) has entered into a binding agreement for a financing of up to US$20 million with Negma Group, the company said Tuesday. The company can avail financing in tranches of up to US$700,000 over a period of 36 months. The fin...
Stock Information
Evaxion Biotech A/S Company Name:
EVAX Stock Symbol:
NASDAQ Market:
Ad
-
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares jumped 104.5% to $0.1916. Digital Transformation Opportunities Corp. (NASDAQ: DTOC) rose 100.7% t...
-
Evaxion Biotech A/S (NASDAQ: EVAX) collaborated with Afrigen Biologics to develop a prophylactic vaccine based on Evaxion's EDEN-discovere...
-
Partnership based on a highly protective vaccine candidate identified by Evaxion’s EDEN™ platform The collaboration will access mRNA technology from the WHO and Medicines Patent Pool’s mRNA Vaccine Technology Transfer Hub Afrigen responsible for the development and co...